National Abortion Totals and Latest Reported Figures
The most recent comprehensive U.S. abortion count comes from the Centers for Disease Control and Prevention, which reports around 619,591 legal induced abortions for 2022, the latest year with finalized data. The Guttmacher Institute, which uses a broader survey method, estimates approximately 930,160 abortions in 2020, and its updated 2023 and 2024 estimates are pending full publication.
These figures represent a decline from the peak around 1.6 million abortions per year in the early 1990s, with the national rate falling to roughly 11.2 abortions per 1,000 women aged 15 to 44 in 2022. The decline reflects falling birth rates, improved contraceptive access, and shifting state laws, as tracked by organizations such as the Kaiser Family Foundation and reported in outlets like Forbes.
State-Level Variation and Post-Roe Shifts
After the Supreme Court's Dobbs decision, states diverged sharply, with some enforcing near-total bans and others protecting access. In 2023, states with restrictive laws such as Alabama, Mississippi, and Louisiana reported very low abortion counts, while states like California, New York, and Illinois saw increases as patients traveled from banned states.
The Guttmacher Institute and the Society of Family Planning track these flows, estimating that in 2023, roughly 100,000 or more women crossed state lines for care, a figure that continues to shape service demand and clinic capacity. The Abortion Care Network and Planned Parenthood Federation of America provide provider directories and state-by-state summaries that quantify these shifts in near real time.
Key Drivers, Demographics, and Economic Context
Abortion rates are closely tied to income, insurance coverage, and clinic availability, with low-income women and women of color disproportionately affected by restrictions. The Hyde Amendment and state-level funding bans limit Medicaid coverage, while telehealth medication abortion has expanded access in permissive states, a trend documented by the FDA and the American College of Obstetricians and Gynecologists.
Companies such as Tesla, Patagonia, and several major law firms have added travel benefits for employees seeking out-of-state reproductive care, signaling a growing intersection between corporate policy and abortion access. The SEC and investor groups increasingly scrutinize these benefits as part of broader environmental, social, and governance reporting, linking annual abortion volumes to workforce planning and brand risk.